The ability of essential amino acids to boost muscle mass in people who suffer from muscle loss.

To evaluate the effectiveness of essential amino acids in primary sarcopenia - RACE

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/063107

Enrollment

Registered

2024-02-23

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M625- Muscle wasting and atrophy, not elsewhere classified

Interventions

Intervention1: Essential Amino Acid(EAA): Essential Amino Acid(EAA)( L Lysine 378mg, L Leucine 342 mg, L Arginine 315 mg, Valine 302mg, L Methionine 302mg, Iso Leucine 302 mg, L Phenylalanine 203 mg,

Eligibility

Inclusion criteria

Inclusion criteria: Healthy individuals 50 years and above age who fall below the cutoff Ishii sarcopenia score.

Exclusion criteria

Exclusion criteria: severe cognitive impairment, poor controlled psychiatric disease, acute infections or known cancer, rheumatoid arthritis, osteonecrosis of the knee, post-traumatic OA, severe hepatic or renal disease, or other condition which could affect the metabolism of nutrients such as cancer, diabetes mellitus and obesity.

Design outcomes

Primary

Measure	Time frame
Ishii Score Muscle strength on DAVIDTimepoint: 0, 4 and 12 weeks	—

Secondary

Measure	Time frame
Deterioration of muscle strengthTimepoint: 6 months	—

Countries

India

Contacts

Public ContactDr Tufail Muzaffar

Sher-i-Kashmir Institute of Medical Sciences

tufailmuzaffar@gmail.com9419418912

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026